Search Page

1

Cite

Share

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.

Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW. Mullins SR, et al. Among authors: leishman aj. J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8. J Immunother Cancer. 2019. PMID: 31511088 Free PMC article.

Cite

Share

2

Cite

Share

Opportunistic sampling of wild native and invasive birds reveals a rich diversity of adenoviruses in Australia.

Vaz FF, Raso TF, Agius JE, Hunt T, Leishman A, Eden JS, Phalen DN. Vaz FF, et al. Among authors: leishman a. Virus Evol. 2020 May 10;6(1):veaa024. doi: 10.1093/ve/veaa024. eCollection 2020 Jan. Virus Evol. 2020. PMID: 32411389 Free PMC article.

Cite

Share

3

Cite

Share

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.

Wilkinson RW, Leishman AJ. Wilkinson RW, et al. Among authors: leishman aj. Front Immunol. 2018 Jun 1;9:1082. doi: 10.3389/fimmu.2018.01082. eCollection 2018. Front Immunol. 2018. PMID: 29910800 Free PMC article. Review.

Cite

Share

4

Cite

Share

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, González-Muñoz A, Parmentier J, Black C, Soden J, Freeth J, Jovanović J, Leyland R, Al-Lamki RS, Leishman AJ, Rust SJ, Stewart R, Jermutus L, Bradley JR, Bedian V, Valge-Archer V, Minter R, Wilkinson RW. Williams GS, et al. Among authors: leishman aj. Oncotarget. 2016 Oct 18;7(42):68278-68291. doi: 10.18632/oncotarget.11943. Oncotarget. 2016. PMID: 27626702 Free PMC article.

Cite

Share

5

Cite

Share

Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy.

Fairchild PJ, Leishman A, Sachamitr P, Telfer C, Hackett S, Davies TJ. Fairchild PJ, et al. Among authors: leishman a. Regen Med. 2015;10(3):275-86. doi: 10.2217/rme.15.6. Regen Med. 2015. PMID: 25933237 Review.

Cite

Share

6

Cite

Share

Directed Differentiation of Human Induced Pluripotent Stem Cells into Dendritic Cells Displaying Tolerogenic Properties and Resembling the CD141⁺ Subset.

Sachamitr P, Leishman AJ, Davies TJ, Fairchild PJ. Sachamitr P, et al. Among authors: leishman aj. Front Immunol. 2018 Jan 8;8:1935. doi: 10.3389/fimmu.2017.01935. eCollection 2017. Front Immunol. 2018. PMID: 29358940 Free PMC article.

Cite

Share

7

Cite

Share

TRITON and beyond: new insights into the profile of prasugrel.

Jakubowski JA, Riesmeyer JS, Close SL, Leishman AG, Erlinge D. Jakubowski JA, et al. Among authors: leishman ag. Cardiovasc Ther. 2012 Aug;30(4):e174-82. doi: 10.1111/j.1755-5922.2011.00263.x. Epub 2011 Feb 17. Cardiovasc Ther. 2012. PMID: 21883999 Free PMC article. Review.

Cite

Share

8

Cite

Share

Immunology: turning basic research into a therapy.

Leishman AJ, Bundick RV. Leishman AJ, et al. Immunol Lett. 2005 Jun 15;99(1):1-7. doi: 10.1016/j.imlet.2004.12.011. Epub 2005 Jan 12. Immunol Lett. 2005. PMID: 15894103 Review.

Cite

Share

9

Cite

Share

TNF-blocking therapies: an alternative mode of action?

Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM, McInnes IB, Garside P. Choo-Kang BS, et al. Among authors: leishman aj. Trends Immunol. 2005 Oct;26(10):518-22. doi: 10.1016/j.it.2005.07.007. Trends Immunol. 2005. PMID: 16087401 Review.

Cite

Share

10

Cite

Share

Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.

Leishman AJ, Sims GP, Sleeman M, Braddock M. Leishman AJ, et al. Expert Opin Investig Drugs. 2011 Jan;20(1):23-39. doi: 10.1517/13543784.2011.540569. Epub 2010 Dec 1. Expert Opin Investig Drugs. 2011. PMID: 21118058 Review.

Cite

Share